MilliporeSigma

Differentiating on Risk vs. Opportunity in Global Biopharma 

What we did:
Insights • Message strategy • Campaign development

Challenge

 

After years of innovation and completing their portfolio for Monoclonal Antibody bioproduction. The problem was, so had all of their competitors. 

 
 

Insight

 

The Biopharma industry is highly concerned about and preoccupied with risk.

 
 

Solution

 

Instead of touting ‘end-to-end’ offerings, affirm the company’s commitment to partner with biopharma to mitigate unprecedented risks of globalization, biosimilars and virtual biotech companies. 

 
 

If you’d like more details about this or other case studies, reach out below.